Pacific Edge Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 100

Employees

  • Stock Symbol
  • PEB

Stock Symbol

  • Share Price
  • $0.15
  • (As of Friday Closing)

Pacific Edge General Information

Description

Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 87 Street David Street
  • PO Box 56
  • Dunedin, 9016
  • New Zealand
+64 0800
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Laboratory Services (Healthcare)
Stock Exchange
NZE
Vertical(s)
Corporate Office
  • 87 Street David Street
  • PO Box 56
  • Dunedin, 9016
  • New Zealand
+64 0800

Pacific Edge Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pacific Edge Stock Performance

As of 13-Nov-2026, Pacific Edge’s stock price is $0.15. Its current market cap is $189M with 1.24B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.15 $0.16 $0.08 - $0.20 $189M 1.24B 741K -$0.02

Pacific Edge Financials Summary

As of 31-Mar-2026, Pacific Edge has a trailing 12-month revenue of $6.75M.

In Thousands,
USD
TTM 31-Mar-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 90,392 90,392 42,082 4,909
Revenue 6,747 6,747 12,926 14,561
EBITDA (20,569) (20,569) (17,983) (18,900)
Net Income (20,994) (20,994) (17,712) (17,989)
Total Assets 10,061 10,061 21,128 39,033
Total Debt 735 735 1,655 2,429
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pacific Edge Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pacific Edge‘s full profile, request access.

Request a free trial

Pacific Edge Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic
Discovery Tools (Healthcare)
Dunedin, New Zealand
100 As of 2025

Hilden, Germany
 

Abbot Park, IL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pacific Edge Competitors (4)

One of Pacific Edge’s 4 competitors is Qiagen, a Formerly VC-backed company based in Hilden, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Qiagen Formerly VC-backed Hilden, Germany
Abbott Corporation Abbot Park, IL
KDx Diagnostics Venture Capital-Backed Los Gatos, CA
Nucleix Venture Capital-Backed Rehovot, Israel
To view Pacific Edge’s complete competitors history, request access »

Pacific Edge Patents

Pacific Edge Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026190756-A1 Methods and systems for patient stratification Pending 14-Mar-2025
US-10131955-B2 Methods for detecting genetic and phenotypic biomarkers of urothelial carcinoma and treatment thereof Active 21-Nov-2013
US-20190203300-A1 Methods for treating urothelial carcinoma using genotypic and phenotypic biomarkers Inactive 21-Nov-2013
ES-2844202-T3 Triage of patients who have asymptomatic hematuria using genotypic and phenotypic biomarkers Active 21-Nov-2013
AU-2014352956-A1 Triaging of patients having asymptomatic hematuria using genotypic and phenotypic biomarkers Active 21-Nov-2013 C12Q1/6886
To view Pacific Edge’s complete patent history, request access »

Pacific Edge Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pacific Edge Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pacific Edge‘s full profile, request access.

Request a free trial

Pacific Edge ESG

Risk Overview

Risk Rating

Updated February, 28, 2025

37.56 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 434

Rank

Percentile

To view Pacific Edge’s complete esg history, request access »

Pacific Edge FAQs

  • When was Pacific Edge founded?

    Pacific Edge was founded in 2001.

  • Where is Pacific Edge headquartered?

    Pacific Edge is headquartered in Dunedin, New Zealand.

  • What is the size of Pacific Edge?

    Pacific Edge has 100 total employees.

  • What industry is Pacific Edge in?

    Pacific Edge’s primary industry is Discovery Tools (Healthcare).

  • Is Pacific Edge a private or public company?

    Pacific Edge is a Public company.

  • What is Pacific Edge’s stock symbol?

    The ticker symbol for Pacific Edge is PEB.

  • What is the current stock price of Pacific Edge?

    As of 13-Nov-2026 the stock price of Pacific Edge is $0.15.

  • What is the current market cap of Pacific Edge?

    The current market capitalization of Pacific Edge is $189M.

  • What is Pacific Edge’s current revenue?

    The trailing twelve month revenue for Pacific Edge is $6.75M.

  • Who are Pacific Edge’s competitors?

    Qiagen, Abbott, KDx Diagnostics, and Nucleix are competitors of Pacific Edge.

  • What is Pacific Edge’s annual earnings per share (EPS)?

    Pacific Edge’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process